SCHEMBL3462201

SCHEMBL3462201

NC(=O)c1[c]cccc1-c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.41
PTGS1 P23219 2/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PTGS2 P35354 2/20 0.40
SLC9A1 P19634 2/20 0.40
SQOR Q9Y6N5 1/20 0.38
IKBKB O14920 3/20 0.38
CHUK O15111 3/20 0.38
BCAT2 O15382 1/20 0.37
MKNK2 Q9HBH9 2/20 0.37
CDC7 O00311 1/20 0.37
PLK4 O00444 1/20 0.37
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
CHEK2 O96017 1/20 0.37
CDK1 P06493 1/20 0.37
FES P07332 1/20 0.37
ROS1 P08922 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663745 0.85 SLC9A1 (0.42) GRM2SLC9A1BCAT2PLK4DAPK3
SCHEMBL8790165 0.85 BCL2L1 (0.44) GRM2PTGS1SLC6A4SLC6A3PTGS2
SCHEMBL2636302 0.84 BCAT2 (0.53) SLC9A1IKBKBCHUKBCAT2FGFR1
SCHEMBL3081965 0.83 MKNK1 (0.40) GRM2IKBKBBCAT2MKNK2MAPK1
SCHEMBL4630355 0.80 IRAK4 (0.41) GRM2MAP4K4IRAK4
SCHEMBL981626 0.80 FGFR1 (0.49) GRM2IKBKBMAP4K4CHEK2FGFR1
SCHEMBL3656937 0.78 PARP10 (0.50) BCAT2CHEK2ALDH1A1
SCHEMBL978717 0.76 PARP10 (0.50) CHEK2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3659396 0.76 CYP11B2 (0.49)
SCHEMBL3660537 0.76 CNR2 (0.43) CDC7FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 GRM2 38/4885PTGS1 197/4885SLC6A4 987/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 GRM2 38/4885PTGS1 197/4885SLC6A4 987/4885
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B GRM2 4303/4885PTGS1 391/4885SLC6A4 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.